Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
de Vries
M K
MK
Brouwer
E
E
van der Horst-Bruinsma
I E
IE
Spoorenberg
A
A
van Denderen
J C
JC
Jamnitski
A
A
Nurmohamed
M T
MT
Dijkmans
B A C
BA
Aarden
L A
LA
Wolbink
G J
GJ
D000068879:Adalimumab; D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000276:immunology* / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab